Corpus Intelligence IC Memo — AZ SPINE & JOINT HOSPITAL 2026-04-26 08:06 UTC
IC Memo — AZ SPINE & JOINT HOSPITAL
Investment Committee Memorandum | AZ | 23 beds | Grade D | EBITDA uplift $3.3M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

AZ SPINE & JOINT HOSPITAL

CCN 030107 | MARICOPA, AZ | 23 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

AZ SPINE & JOINT HOSPITAL is a 23-bed community hospital in MARICOPA, AZ with $45.1M in net patient revenue and a 19.4% operating margin. The hospital serves a payer mix of 44.9% Medicare, 0.0% Medicaid, and 55.1% commercial.

Thesis: Turnaround. Our ML models identify $3.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 19.4% to 26.7% (+736bps).

Net Revenue HCRIS$45.1M
Current EBITDA COMPUTED$8.7M
Operating Margin COMPUTED19.4%
Occupancy HCRIS15.9%
Revenue / Bed COMPUTED$2.0M
Net-to-Gross HCRIS19.7%
Distress Probability MLnan%

2. Market Context & Competitive Position

124
AZ Hospitals
-0.8%
State Median Margin
35
Comparable Hospitals

AZ has 124 Medicare-certified hospitals with a median operating margin of -0.8%. The target's margin of 19.4% places it above the state median. Among 35 size-comparable peers (12-46 beds), the median margin is -3.1%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (12-46), prioritizing same-state peers. 35 hospitals in the comp set.

HospitalStateBedsRevenueMargin
AZ SPINE & JOINT HOSPITAL (Target)AZ23$45.1M19.4%
ARIZONA GENERAL HOSPITALAZ16$97.1M10.4%
THE CORE INSTITUTE SPECIALTY HAZ28$91.2M9.2%
MT. GRAHAM REGIONAL MEDICAL CEAZ25$75.2M-2.8%
COBRE VALLEY REG. MEDICAL CENTAZ25$74.9M-10.3%
COPPER QUEEN COMM. HOSP.AZ14$63.5M6.6%
MT. GRAHAM REGIONAL MEDICAL CEAZ25$49.4M-6.8%
BANNER PAYSON MEDICAL CENTERAZ25$49.3M0.0%
WINSLOW MEMORIAL HOSPITALAZ25$40.1M-6.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $3.3M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$948K+210bp18mo
Cost to Collect4.5%2.5%$902K+200bp12mo
Denial Rate Reduction12.0%6.5%$893K+198bp12mo
A/R Days Reduction5200.0%3800.0%$549K+122bp9mo
Clean Claim Rate88.0%96.0%$29K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$948K
Cost to Collect
$902K
Denial Rate Reduction
$893K
A/R Days Reduction
$549K
Clean Claim Rate
$29K
Total EBITDA Uplift$3.3M
Current EBITDA$8.7M
+ RCM Uplift+$3.3M
Pro Forma EBITDA$12.1M
Current Margin19.4%
Pro Forma Margin26.7%
WC Released (1x)$1.7M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$13.4M$90.9M6.76x46.5%
Base (11x exit)10.0x11.0x$13.4M$104.3M7.76x50.6%
Bull Case9.0x11.0x$12.1M$119.7M9.89x58.1%
Bull (12x exit)9.0x12.0x$12.1M$134.1M11.08x61.8%
Bear Case11.0x10.0x$14.8M$69.9M4.73x36.4%
Bear (11x exit)11.0x11.0x$14.8M$81.7M5.52x40.7%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 15.9%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 35 hospitals with 12-46 beds
  • Same-state prioritization (n=36)
  • Comp margins: P25=-10.1% / P50=-3.1% / P75=7.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.